Omnicell (OC9) AI Stock Analysis

Omnicell

(Frankfurt:OC9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationStrong operating and free cash flow indicates that recent earnings are supported by real cash generation, giving Omnicell greater flexibility to fund product development, customer deployments, and debt reduction while improving resilience through the next several quarters.

Negative Factors

Weak and volatile revenue trendThe sharp TTM revenue decline and historically uneven top-line performance indicate that demand conversion remains inconsistent. This can limit operating leverage, complicate planning, and make sustained profitability improvement dependent on a more reliable refresh and implementation cycle.

Omnicell (OC9) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.66B
Dividend Yield: ―
Average Volume (3M): 100
Price to Earnings (P/E): 37.3
Beta (1Y): 0.14
Revenue Growth: 0.44%
EPS Growth: 118.20%
Country: Germany
Employees: 3,580
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...

Omnicell Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-0.61%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was broadly positive. The company exceeded third-quarter revenue and EBITDA guidance, raised full-year EBITDA and EPS guidance, reported growing and increasingly mature pipeline activity, and highlighted customer validation for Titan XT and OmniSphere. The main challenges were timing variability in back-end-weighted bookings, modest near-term top-line growth, lower fourth-quarter revenue guidance, memory-cost pressure, a modest 340B-related ARR impact, and the multi-year timeline for OmniSphere monetization. The positive operating results, strategic progress, and pipeline commentary significantly outweighed the stated challenges.

Positive Updates

Third-Quarter Revenue and EBITDA Beat Guidance

Third-quarter total revenue was $308 million, above the high end of the previously provided $301 million to $307 million guidance range. Non-GAAP EBITDA was $45 million, above the high end of the $32 million to $37 million guidance range.

Negative Updates

Modest Top-Line Growth During Early Refresh Cycle

Management noted that top-line growth remains modest, describing this as a natural feature of the early stages of the refresh cycle.

Company Guidance

For the fourth quarter of 2026, Omnicell expects total revenue in the range of $295 million-$301 million, non-GAAP EBITDA in the range of $30 million-$36 million, and non-GAAP earnings per share in the range of $0.41-$0.49; for full-year 2026, the company reiterated product bookings in the range of $425 million-$560 million, total revenue in the range of $1.225 billion-$1.231 billion, product revenue in the range of $684 million-$687 million, service revenue in the range of $541 million-$544 million, and year-end 2026 ARR in the range of $660 million-$670 million, while raising non-GAAP EBITDA guidance to the range of $187 million-$193 million and non-GAAP earnings per share guidance to the range of $2.48-$2.56; full-year 2026 bookings are expected to be back-end weighted, the company continues to target the first half of 2027 for general availability of OmniSphere, anticipates a modest impact on its 2026 ARR from the 340B Drug Pricing Program environment, and expects roughly half of the approximately $6 million in incremental second half memory cost in the fourth quarter.

Omnicell Risk Analysis

Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.

Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

3 New Risks

1.Our products use raw materials and components that may be subject to price fluctuations, shortages, or interruptions of supply, and if we are unable to maintain supply sources for such raw materials and components, or if such sources fail to satisfy our supply requirements, in particular with regard to semiconductor chips, we may experience a loss of sales, increased component costs, and reduced profitability.Q2, 2025

2.Failure to generate new sales and any reduction in the demand for or adoption of our medication management solutions, medication packaging systems, or related services would reduce our revenues.Q2, 2025

3.Our international operations may subject us to additional risks that can adversely affect our business, operating results, cash flow, or financial condition.Q2, 2025

Omnicell Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:OC9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHR	69Neutral	$772.16M	72.24	3.01%	―	12.93%	―
OPRX	66Neutral	$175.55M	38.63	3.60%	―	-5.82%	―
CCLD	59Neutral	$74.79M	24.64	16.56%	―	15.07%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DH	47Neutral	$162.22M	-0.71	-78.52%	―	-4.99%	39.52%
HCAT	44Neutral	$127.18M	-0.43	-129.70%	―	-7.54%	-143.41%

* Healthcare Sector Average

Performance Comparison

DE:OC9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:OC9	Omnicell	32.60	4.20	14.79%
OPRX	Optimizerx Corporation	9.41	-9.37	-49.89%
CCLD	Carecloud, Inc.	1.72	-1.16	-40.28%
PHR	Phreesia	12.44	-10.10	-44.81%
HCAT	Health Catalyst	1.58	-1.45	-47.85%
DH	Definitive Healthcare Corp. Class A	1.13	-1.65	-59.35%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Omnicell AI Stock Analysis